MRNA vs INSM
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 01, 2026
MRNA
INSM
Investment Advisor Scores
INSM
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | INSM | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 16.3666 | INSM |
| PEG Ratio | 0 | 1.0916 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.1% | 296.1% | INSM |
| Earnings Growth | -85.1% | 0.0% | INSM |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 35.5/100 | 37.4/100 | INSM |
| Profit Margin | -141.4% | -76.9% | INSM |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | EXTENDED | SELL | MRNA |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
MarkupPrice above SMA50, rising 50-day trend (33.8% over 20 days), RSI 64
INSM
MarkupPrice above SMA50, rising 50-day trend (8.7% over 20 days), RSI 52
Fundamentals Snapshot
| Metric | MRNA | INSM |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -28.2 | 151.9 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 3.0% |
| Gross Margin | -0.7% | 0.8% |
| Operating Margin | -5.6% | -0.2% |
| EPS | -7.71 | -4.02 |
| Dividend Yield | — | — |